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ABSTRACT 
Objective. To compare the effects of a prebiotic supplement versus a low FODMAP diet in 
patients with functional gut disorders. Design. Two-centre, parallel, randomized, double-
blind study comparing the effects of a prebiotic supplement (2.8 g/day Bimuno, Clasado 
Biosciences, Jersey, Channel Islands) with a placebo diet (prebiotic group) versus and a 
placebo supplement (2.8 g per day xylose) with a low FODMAP diet (LFD group). The 
study consisted of 1 week of pretreatment (days 1-7), 4 weeks of treatment (days 8-35) 
and 2 weeks of post-treatment follow-up (days 36-49). All patients received dietary 
instructions in similar intervention visits. The following outcomes were measured: a) the 
number of daytime gas evacuations over the course of 2 days were measured by means of 
an event marker; b) the volume of gas evacuated over the course of 4 hours after 
consumption of a probe meal were measured via a rectal tube; and c) the microbiota 
composition was measured by faecal Illumina MiSeq sequencing. 
Results. Both treatments improved the symptoms to a similar extent. After termination of 
the prebiotic treatment, the symptomatic improvement persisted for 2 weeks. In contrast, 
after termination of the LFD diet, a rebound was observed, and by 2 weeks post-treatment, 
the symptoms were more severe than during the treatment phase. In the prebiotic group, 
the counts of bifidobacteria increased, and the counts of sulphate-producing species 
decreased, while the opposite effects were observed in the LFD group. 
Conclusion. Both the LFD and the B-GOS prebiotic administration were similarly effective 
at treating gas-related symptoms in patients with functional gut disorders. However, both 
strategies had different consequences after treatment discontinuation; while the 
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improvement of symptoms persisted 2 weeks after prebiotic administration was 
discontinued, the symptoms relapsed after the termination of the LFD. 
Keywords: intestinal gas, microbiota, prebiotics, low FODMAP diet, functional 
gastrointestinal symptoms 
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Summary ‘box’ 
1. What is already known about this subject?
• Diets low in fermentable residues, such as low FODMAP diet, improve gas-related
symptoms in patients with functional gut disorders. 
• Paradoxically, a galactooligosaccharide prebiotic, B-GOS, that is not absorbed in
the small bowel and is selectively fermented by colonic microbiota, produces a 
similar effect on gas-related symptoms. 
2. What are the new findings?
• Both a low FODMAP diet (plus a placebo supplement; 2.8 g per day xylose) and a
prebiotic supplement (2.8 g/day Bimuno, Clasado Biosciences, Jersey, Channel 
Islands; plus a placebo diet) were similarly effective at treating gas-related 
symptoms in patients with functional gut disorders. 
• However, both strategies had different consequences after treatment
discontinuation; while the improvement of symptoms persisted 2 weeks after 
prebiotic administration was discontinued, the symptoms relapsed after the 
termination of the 
3. How might it impact on clinical practice in the foreseeable future?
• Since dietary restrictions, particularly the low FODMAP diet, are cumbersome to
follow, these results present an alternative patient management strategy. 
• Furthermore, given the sustained effect of B-GOS compared to the reversible
effects of the low FODMAP diet, intermittent treatment with B-GOS might represent 
an additional advantage over the continuous treatment required with the low 
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FODMAP diet. 
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INTRODUCTION 
A significant proportion of patients with functional gut disorders complain of 
symptoms that they attribute to intestinal gas, such as flatulence, abdominal bloating, 
distension and borborygmi 
1
. A series of studies has shown that diets low in fermentable
residues, i.e., those that contain low amounts of products that escape small bowel 
absorption and are fermented by colonic microbiota, improve gas-related symptoms in 
these patients. Similar effects have been observed with different diets 
2-5
, among which a
diet low in fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) has 
become particularly popular and widely used 
4 6
. Paradoxically, a galactooligosaccharide
prebiotic, B-GOS, that is not absorbed in the small bowel and is selectively fermented by 
colonic microbiota, produces a similar effect on gas-related symptoms 
7
. Initially, this
product increases the fermentive activity of microbiota and, consequently, increases gas 
production, but this effect declines after a relatively short adaptation period (1-2 weeks) 
with a shift in microbiota metabolism towards more efficient, low-gas producing pathways 
8
9
. In contrast, some data have indicated that in the long run, a low FODMAP diet with 
restricted fermentable substrates may negatively affect gut microbiota 
10-12
.
Based on these data, we hypothesized that both approaches, i.e., a low FODMAP 
diet and a B-GOS prebiotic supplement, would improve gas-related symptoms during the 
period of administration but would have different consequences after discontinuation, due 
to their specific effects on gut microbiota. Hence, our aim was to compare the effects of a 
low FODMAP diet versus the B-GOS prebiotic supplement on gas-related symptoms and 
colonic microbiota during a 4-week treatment period and a 2-week post-treatment period. 
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To this aim, consecutive patients complaining of excessive anal gas evacuation, i.e., 
flatulence, were recruited. We compared the effects of a low FODMAP diet plus a placebo 
supplement versus a placebo diet (Mediterranean-type) plus the B-GOS prebiotic 
supplement on gas-related symptoms and anal gas evacuation. The effects of the 
treatments were evaluated during basal conditions, after a 3-day challenge diet and after a 
probe meal. 
MATERIAL AND METHODS 
Study design 
This study was a randomized, two-centre, parallel and double-blind study performed 
between August 2014 and July 2015 in 2 tertiary care referral centres. The study protocol 
was registered with ClinicalTrials.gov (NCT02210572). All co-authors had access to the 
study data and reviewed and approved the final manuscript. The study compared the effect 
of a prebiotic supplement plus a placebo diet (prebiotic group) versus a placebo 
supplement plus a low FODMAP diet (LFD group; see sections on supplement products 
and treatment diets below). The study lasted 7 weeks (49 days) with 3 phases: a 1-wk 
pretreatment phase (days 1-7), a 4-wk treatment phase (days 8-35) and 2-wk post-
treatment phase (days 36-49) (Figure 1). 
The primary outcome was the effect of the treatments on gut microbiota 
composition, specifically the relative abundance of bifidobacteria. Secondary outcomes 
were intestinal gas production, as an index of microbiota activity, and digestive sensations. 
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Randomization and masking 
Participants were randomized using a block design (n=10 per block) by a computer-
generated randomization list. Participants did not know which treatment they were 
assigned, and all patients received dietary instructions following the same schema of 
intervention visits. The investigators performing the tests and the clinical follow-up were 
blinded to the intervention (supplement and diet). 
Participants 
Patients fulfilling the criteria of having a functional gastrointestinal disorder and 
complaining of excessive anal gas evacuation (i.e., flatulence) (35 women, 5 men; age 
range 24 - 73 years) participated in the study. Antibiotic consumption during the previous 2 
months was an exclusion criterion. Participants were instructed to fill out a clinical 
questionnaire to evaluate bowel habits and gastrointestinal symptoms. Subjects gave 
written informed consent to participate in the study. The protocol for the study had 
previously been approved by the Institutional Review Board of University Hospital Vall 
d´Hebron. 
Supplement product 
During the treatment phase (days 8-35) participants consumed 1 sachet per day of 
either prebiotic (2.8 g per day Bimuno containing 1.37g B-GOS, Clasado Biosciences , 
Jersey, Channel Islands) or placebo (2.8 g xylose). 
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Dietary instructions 
The treatment diet, either a low FODMAP or a placebo diet, was administered 
during the first 23 days of the treatment phase (days 8-31). Participants were put on a 
standard, highly flatulogenic diet during 3-day periods at the end of the pretreatment phase 
(days 5-7) and the treatment phase (days 33-35). During the first 4 days of the 
pretreatment phase (days 1-4) and the post-treatment phase (days 36-49), the participants 
consumed their habitual diet. For the duration of the study, patients were not allowed to 
consume any fermented dairy products or any tablets, pills or food supplements containing 
pre- or probiotics other than those provided. A dietician provided dietary instructions and 
checked adherence to the diets using structured consumption questionnaires. 
Treatment diets 
Low FODMAP diet. The food list for the diet was based on published information 
adapted to local eating habits 
13-15
. The diet specifically excluded a) dairy products, b) fruit,
including apples, pears, peaches, apricots, cherries, mangoes, watermelon, melon, and 
prunes, c) legumes, including chickpeas, white beans, lentils, and soya beans, d) 
vegetables, including artichokes, asparagus, beetroot, Brussels sprouts, broccoli, cabbage, 
garlic, leeks, onions, peas, lettuce, and cauliflower, e) cereals, including bread, rye, and 
oats, and f) sweeteners. 
Placebo diet. The diet was balanced and Mediterranean-type 
2
, including the 
following every day: a) meat, fowl, fish, or eggs, b) vegetables, salad or legumes, c) bread, 
rice, pasta, potatoes or cereals, d) dairy products, and e) fruits. 
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Challenge diet 
The challenge diet consisted of: a) breakfast of wholemeal cookies (39 g) plus 
coffee, tea and/or milk, b) lunch of white beans (200 g), mixed vegetables (250 g) or 
chickpeas (200 g) and wholemeal bread (50 g), plus meat, fowl or fish and fruit (banana, 
figs peaches or prunes), and c) dinner of vegetable soup (200 mL), wholemeal bread (50 g) 
and fruit (banana, figs, peaches or prunes). 
Outcomes 
The outcomes were measured during 3-day periods at 5 time points throughout the 
study: in the pretreatment phase just before and during the challenge diet (days 2-4 and 5-
7, respectively), in the treatment phase just before and during the challenge diet (days 30-
32 and 33-35, respectively), and at the end of the post-treatment phase (days 47-49) 
(Figure 1). 
Daily symptom questionnaire 
During the 3 days of each evaluation period, the participants were instructed to fill 
out daily questionnaires that included the following parameters: (a) subjective sensations of 
flatulence (defined as anal gas evacuation), abdominal bloating (pressure/fullness), 
abdominal distension (sensation of girth increase), borborygmi and abdominal 
discomfort/pain using 0–10 analogue scales, (b) digestive well-being using a 10-point scale 
graded from +5 (extremely pleasant sensation/satisfaction) to −5 (extremely unpleasant 
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sensation/dissatisfaction), and (c) mood on similar scale graded from +5 (very positive) to 
−5 (very negative). For each symptom, the scores for each 3-day period were averaged. 
This questionnaire has been previously used and has been shown to be sensitive enough 
to detect the effects of dietary interventions in different populations 
2 16-18
.
Number of anal gas evacuations 
The number of anal gas evacuations during the last 2 days of each evaluation 
period were measured and averaged. Participants were instructed to carry an event marker 
(Hand Tally Counter No 101, Digi Sport Instruments, Shanggiu, China) during the day and 
to use it to register each passage of anal gas. This method has been previously used with 
reproducible and consistent results 
2 8 9 16
; furthermore, studies measuring the number of
gas evacuations by an event marker and continuously recording anal gas evacuations have 




Response to a probe meal 
The test was performed the day after the pretreatment and treatment phases. 
Participants reported to the laboratory after an overnight fast and consumed a probe meal. 
The probe meal consisted of a ham omelette (1 egg, 30 g sliced ham cooked with 5 g oil), 
46 g of white bread, 10 g of butter, 25 g of jam and 200 mL of fruit juice (400 Kcal, 350 mL 
total volume, 1.5 g of fibre). 
The volume of gas evacuated by anus was measured for 4 h after the probe meal, 
as previously described 
16 23 24
. Briefly, gas was collected using a rectal balloon catheter (20
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F Foley catheter, Bard, Barcelona, Spain) connected via a gas-tight line to a barostat, and 
the volume was continuously recorded. The intrarectal balloon was inflated with 5 mL of 
water to prevent anal gas leaks. 
Patients’ perceptions of abdominal sensations were measured every 30 min during 
the 4-h gas collection period using the same scales as described above: 0 to 10 scales for 
scoring abdominal bloating (pressure/fullness), abdominal distension (sensation of girth 
increase), borborygmi and abdominal discomfort/pain and  – 5 to + 5 scales for scoring 
digestive well-being and mood. 
Metabolomic analysis 
Urine was collected for 24 h during the last day of the pretreatment and treatment 
periods (days 7 and 35, respectively) from 22 patients, with 11 from each treatment group. 
For each sample, a one-dimensional 1H NMR spectrum was acquired according to the 
standard recommendations 
25 26
. Analyses of the histamine levels and P-cresol level in the
urine samples were performed by mass spectroscopy. 
Microbiota composition 
Faecal samples were collected from 40 patients during the pretreatment, treatment 
and post-treatment phases (days 5, 32 and 49, respectively) (Figure 1). After collection and 
homogenization, the samples were immediately frozen by the participants in their home 
freezers at -20 ºC and later brought to the laboratory in a freezer pack, where they were 
stored at -80°C. Microbiota analysis was performed as previously described (see 
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Supplemental material). 
Statistical analysis 
Sample size calculation. Sample size calculation was performed based on the effect 
of the prebiotic B-GOS on fecal bifidobacteria. In previous studies 
8
, B-GOS cosumption
increased relative abundande of bifidobateria in 13 out 20 subjects (65%); by contrast, low 
FODMAP diet did not induce this effect 
12
. Assuming a bifidobacteria increase in 65% of
patients on B-GOS and in less th n 15% of patients on low FODMAP diet, it was estimated 
that a sample size of 18 individuals per group would provide a 90% power to detect 
statistical differences between groups. 
Metabolomic analysis. Differences from pre- and post-treatment spectra were used 
for comparisons between groups. 
Microbiota analysis. The Shapiro-Wilk test was used to assess the normality of the 
data, and pairwise comparisons were made between the study groups with the non-
parametric Kruskal-Wallis one-way analysis of variance test, which compares means 
between groups. A false discovery rate (FDR) of corrected p-values was taken into account 
when considering the significance of the results. 
Overall comparisons. In each group, the effect of treatment (treatment minus 
pretreatment) was measured at the baseline, after the challenge diet and after the probe 
meal. The effects of treatment were compared between the prebiotic and the LFD group. 
The means (±SE) of the measured variables were calculated. The Kolmogorov-Smirnov 
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test was used to check the normality of the data distribution. Parametric normally 
distributed data were compared by Student’s t-test for paired or unpaired data; otherwise, 
the Wilcoxon signed-rank test was used for paired data, and the Mann-Whitney U test was 




Forty-four patients were selected and included in the study (Figure 2 and Table 1). 
All patients (n=44) had a functional disorder diagnosis based on the Rome III criteria 
27 28
(Table 1). No demographic or clinical differences were found between the prebiotic and 
LFD groups (Table 1). 
Symptoms and gas evacuation 
Pre-treatment phase. On their habitual diets, the patients exhibited mild to moderate 
symptoms (Figure 3) and recorded 15±1 evacuations of gas during the daytime (Figure 4). 
No significant differences in the above parameters were detected between the study 
groups (Figures 3, 4). 
Treatment phase. Both treatments improved the symptom scores in the daily 
questionnaires (Figure 3). The LFD diet, but not the prebiotic treatment, significantly 
reduced the number of gas evacuations (Figure 4). No differences in the effect of treatment 
(treatment values minus pretreatment values) were detected between the study groups 
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(p=0.287 by MANOVA). 
Post-treatment phase. With the prebiotic treatment, the symptomatic improvement 
was maintained 2 weeks after treatment termination; to note, digestive well-being further 
improved. In contrast, after the LFD diet was terminated, a rebound was observed, and by 
2 weeks post-termination, the symptoms were greater than during treatment phase (Figure 
3), although the change (from treatment values to post-treatment values) was not 
significantly different between groups (p=0.091 by MANOVA). In the prebiotic group, the 
number of gas evacuations after treatment was slightly (not significantly) lower than in the 
pretreatment and the treatment phases. In contrast, in the LFD group, the number of gas 
evacuations after treatment increased compared to the treatment level (p=0.056 vs 
treatment; p=0.059 vs change in prebiotic group) (Figure 4). 
Response to challenge diet 
Pre-treatment phase. The challenge diet increased the intensity of symptoms 
similarly in both groups (Figure 5). The number of daytim  gas evacuations increased in 
the prebiotic and the LFD groups (by 12±4 evacuations and 6±2 evacuations, respectively; 
p=0.160 between groups; p≤0.005 vs habitual diet for both). 
Treatment phase. The effect of the challenge diet on symptoms (changes in daily 
symptoms) during treatment was similar that observed before treatment in both groups and 
the effect was not different between treatments (p=0.148 by MANOVA) (Figure 5). Since 
the symptoms during both treatments were at lower levels than in the pretreatment phase, 
the symptoms due to the challenge diet were lower during in the treatment phase than 































































Confidential: For Review Only
during the pretreatment phase in both groups. The increase in the number of gas 
evacuations in response to the challenge diet was similar to the increase observed during 
the pretreatment phase in both groups (increase of 12±3 evacuations in the prebiotic group 
and 7±2 evacuations in the LFD group; p=0.117 between groups; p≤0.002 vs habitual diet 
for both). 
Response to probe meal 
Pre-treatment phase. After the probe meal, participants reported symptoms (Figure 
6), and both the symptom scores as well as the total volume of gas evacuated by anus in 
the 4-hour postprandial period (149±20 mL in the prebiotic group and 173±22 mL in the 
LFD group) were similar in both groups (Figure 6). 
Treatment phase. In both groups, the probe meal produced the same volume of gas 
in the treatment phase (140±17 mL in prebiotic and 160±29 mL in LFD group) and in the 
pretreatment phase, but overall, the tolerance of the probe meal was somewhat better 
during the treatment phase in both groups (Figure 6), without differences between groups 
(p=0.570 by MANOVA). 
Metabolomic analysis 
The initial analysis was performed using a fingerprinting approach. Significant 
differences between both treatments were detected in five integrated regions of the 
spectrum. These regions were located at 7.911-7.898 ppm, 4.165-4.148 ppm, 2.789-2.786 
ppm, 2.003-1.956 ppm, and 1.677-1.662 ppm. Using the Human Metabolome Database 





































































, only two of these regions were identified as previously
described metabolites, xanthine and an unsaturated fatty acid. A partial least squares 
discriminant analysis (PLS-DA) classifi using the five integrated regions that were different 
between groups showed good discrimination between treatments: All patients were 
correctly classified according to their treatment. In addition to the integrated regions, the 
metabolite 4-deoxythreonic acid, a metabolite previously found to decrease in urine 
incubated with E. coli, was found to have significant weight in the model 
31
. No significant
differences were found in the concentrations of histamine or P-cresol in urine samples 
according to treatment or group. 
Changes in faecal microbiota 
In the LFD group, treatment was associated with a decrease in the relative 
abundance of unknown Clostridiales and Bacteroides species and an increase in the 
abundance of species belonging to Ruminococcaceae (mucin degraders), 
Desulphovibronaceae (sulphate-reducing bacteria) and Ent robacteriaceae families (Table 
2). In the post-treatment phase, changes in several bacterial taxa were detected, including 
a remarkable increase in the abundance of members of the Bifidobacterium genus (Table 
2). In the prebiotic group, the abundance of two Lachnospiraceae species increased during 
treatment (Table 3). There was a reduction in the abundance of Parabacteroides, 
Oscillospira, Barnesiellaceae, Christensenellaceae, and Bilophila wadsworthia species. 
Figure 7 shows trade-off in response to the interventions between the abundance of 
Bilophila wadsworthia and that of bifidobacteria. In the LFD group, the counts of 
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bifidobacteria went down during treatment, but rebounded in the post-treatment phase, 
whereas in the prebiotic group, they showed a positive change during treatment and no 
change after treatment. In contrast, the change in the counts of Bilophila wadsworthia 
during treatment was positive in the LFD group and negative in the prebiotic group, and the 
trend persisted in the post-treatment phase. Interestingly, in the LFD group, the increase in 
gas frequency in the post-treatment phase correlated with the increase in Bilophila 
wadsworthia abundance (r=0.48, p=0.050), and this correlation was absent in the prebiotic 
group (r=0.07, p=0.796). 
DISCUSSION 
Our study shows that both the LFD and the B-GOS prebiotic supplement are 
similarly effective in the treatment of gas-related symptoms in patients with functional gut 
disorders. However, both strategies had different consequences after treatment 
discontinuation. While the improvement of symptoms persisted 2 weeks after prebiotic 
administration, symptoms relapsed after discontinuing the LFD. 
Most likely, the improvement in symptoms in response to each treatment is achieved 
via different mechanisms. The clinical outcome associated with the LFD in our study is 
similar to that previously reported 
4 6 11
. The LFD reduced gas production, and conceivably
this effect contributed to the improvement of gas-related symptoms. Diets low in residues 
are associated with lower volumes of colonic content 
32
, and conceivably this is also the
case with the LFD. Intestinal loads of FODMAPs have been shown to increase the volume 
of content within the small bowel 
33
, but whether the intestinal content on an LFD is lower
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than on a normal diet without an excess of FODMAPs remains unproven. 
The improvement of gas-related symptoms due to supplementation with the B-GOS 
prebiotic in our study is consistent with previous observations 
7
. However, the mechanisms
by which B-GOS improves symptoms are not clear. As described above, B-GOS is a non-
absorbable, fermentable product; consequently, it serves as substrate for colonic 
microbiota and at initial administration increases intestinal gas production. However, 
continuous B-GOS administration elicits an adaptation phenomenon, resulting in a 
progressive decrease in gas production back to pre-administration levels by 7-10 days of 
treatment 
8 9
 and a change in gut microbiota profile 
7 8
, which is likely the cause of
adaptation. Furthermore, B-GOS has shown anti-inflammatory effects, and it could also 
reduce intestinal hypersensitivity, a characteristic feature in patients with functional gut 
disorders that leads to symptoms in response to normal gut contents 
34 35
. It is not known
whether the effects of B-GOS administration on symptoms and microbiota are product-
specific or are common to other prebiotics. 
Symptom improvement persisted 2 weeks after termination of B-GOS 
administration. This post-administration effect is probably related to the changes in 
microbiota, and the current data do not indicate for how long it may persist. In contrast to 
the post-treatment effect of B-GOS, symptoms relapsed 2 weeks after LFD discontinuation, 
reflecting a cessation of the influence of LFD on the intraluminal environment when 
replaced by the patients’ habitual diets. 
Potentially beneficial effects of B-GOS on microbiota include the increase in 
Lachnospiraceae, which produce butyrate and other short chain fatty acids, and the 
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decrease in Bilophila wadsworthia, a sulphate-reducing bacterium that has been found to 
play a role in individuals complaining of excess flatus 
16
 and has been associated with
intestinal inflammation in experimental models 
36
. The changes in microbiota induced by
LFD were distinctively different than those induced by B-GOS, particularly in relation to the 
abundance of bifidobacteria (decreased with LFD and increased with B-GOS) and Bilophila 
wadsworthia (increased with LFD and decreased with B-GOS). 
As in previous studies in patients with functional gut disorders 
16
, the challenge diet
in the pretreatment period substantially increased anal gas evacuations and symptom 
scores, and a similar increase was observed in the pretreatment and treatment periods. 
However, since  the patients felt better with the treatments, the challenge was better 
tolerated in terms of absolute symptom scores. In contrast to what we anticipated, 
tolerance of the challenge diet was similar with both treatments; conceivably, the challenge 
was too strong and overcame the potential influences of the treatments. 
Likewise, the probe meal was better tolerated, i.e., with lower postprandial symptom 
scores, during both treatments than before both treatments, but without differences 
between groups. Furthermore, the treatments did not affect the volume of gas produced 
after the probe meal. This unexpected lack of differences could be because the probe meal 
was administered after 3 days on the challenge diet, which provided a heavy colonic load 
and blurred the effect of treatment. Indeed, intestinal gas production depends not only on 
recent but also on previous fermentable residue loads 
37
.
The treatments produced different changes in urine metabolites. Although the 
significance of the changes is difficult to ascertain, the metabolomic analysis provided a 
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good discrimination between groups, which served as an indirect index of the adherence to 
the dietary instructions. Previous studies have shown that a low FODMAP diet modulates 
histamine levels in urine 
38
 and that P-cresol, a bacterial protein fermentation metabolite,
reflects the influence of diet on amino acid fermentation in the colon 
39
; however, no
changes in these metabolites were detected in our study. 
From a practical perspective, our study indicates that in the short run, daily 
administration of B-GOS prebiotic is equally effective as an LFD. Since dietary restrictions, 
particularly the LFD, are cumbersome to follow, these results present an alternative patient 
management strategy. Furthermore, given the sustained effect of B-GOS compared to the 
reversible effects of LFD, intermittent treatment with B-GOS might represent an additional 
advantage over the continuous treatment required with LFD. Recent data indicate that 
simultaneous administration of a probiotic may prevent the potentially deleterious 
influences of LFD on microbiota 
11
. Possibly, the combination of different therapies may
have synergistic effects. Gas-related symptoms may benefit from individualized treatment 
with diet, prebiotics and/or probiotics in single or combined therapy. Ideally, individual 
treatment strategies would be based on biological markers, including microbiota metabolic 
activity and composition. 
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FIGURE LEGENDS 
Figure 1. Experimental design. Note the color code: pre-treatment phase white, 
treatment black and post-treatment grey. 
Figure 2. Flow chart. 
Figure 3. Baseline symptoms measured by daily questionnaires pre-treatment (days 2-
4, white), in the treatment phase (days 30-32, black) and in the post-
treatment phase (day 47-49, grey) (LFD n=21; prebiotic group n=19). Data 
are average over each 3-day periods. 
Figure 4. Number of daytime anal gas evacuations during the last 2 days of each 
evaluation phase: pre-treatment (Pre: days 3-4, white), treatment (Tx: days 
31-32, black) and post-treatment (Post: days 48-49, grey) (LFD n=21; 
prebiotic group n=19). 
Figure 5. Effect of challenge diet on symptoms measured by daily questionnaires pre-
treatment (days 5-7, white) and in the treatment phase (days 33-35, black) 
(LFD n=21; prebiotic group n=19). Data are average over each 3-day 
periods. In each group the change during treatment from pre-treatment 
phase is shown. 
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Figure 6. Symptoms in response to probe meal in the pre-treatment (day 5, white) and 
in the treatment phase (day 33, black) (LFD n=21; prebiotic group n=19). 
Figure 7. Effect of treatment on relative abundance in Bifidobacterium and Bilophila 
wadsworthia. Figure shows changes during treatment (from pre-treatment 
phase) and after treatment (from treatment phase). Overall differences were 
tested by non-parametric Kruskal-Wallis analysis of variance on ranks, and 
the Mann-Whitney test was used for post-hoc comparisons (LFD n=21; 
prebiotic group n=19). Data are median and interquartile range. 































































Confidential: For Review Only
Table 1. Demographics and clinical data 
    STUDY GROUPS 
Prebiotic (n=24)       Low FODMAPs (n=21)    p value 
- Age (range), years  43 (24-73)  48 (26-69)  0.309 
- Sex, M/F 2/17  3/18  1 
- Diagnosis, IBS-a/IBS-d/FAP  9/5/5  9/5/7  0.889 
- Bowel habit, No./wk 6.1±0.8  5.9±0.7   0.679 
- Stool form, Bristol score 4.9±1.0  4.8±1.0  0.797 
- Symptom duration, years  4.7±1.8  4.4±1.5  0.694 
- Flatulence, score* 5.2±3.0  5.3±2.3  0.976 
- Abdominal bloating* 5.4±2.4  5.9±2.2  0.474 
- Abdominal distension* 5.7±2.2  6.3±2.2  0.374 
- Borborigmi*   3.1±2.3  3.8±2.5  0.348 
- Discomfort/pain, score* 4.7±1.8  4.8±2.9  0.975 
FAP, functional abdominal pain; * average of daily measurements over 3-day pre-treatment 
evaluation period 
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Table 2. Changes in bacterial taxa during and after intervention in the LFD group
1 Non-parametric repeated measures Friedman test. 




Clostridiales; unknown genus; species 324 <0.01  
Lachnospiraceae; unknown genus; species 40 <0.02  
Ruminococcaceae; unknown genus; species 53 <0.03  
Bacteroidales; unknown genus; species 39 <0.03  
Ruminococcaceae; unknown genus; species 486 <0.03  
Bacteroides; species 293 <0.03  
Desulfovibrionaceae; unknown genus; species 508 <0.05  
Enterobacteriaceae; unk own genus ;species 217 <0.05  




Streptococcus; species 72 <0.01  
Holdemania; species 509 <0.01  
Erysipelotrichaceae; genus unknown ;species 27 <0.03  
Clostridiales; genus unknown; species 122 <0.03  
Barnesiellaceae; genus unknown ;species 314 <0.03  
Clostridiales; genus unknown;species 292 <0.03  
Clostridiales; genus unknown; species 251 <0.05  
Lachnospiraceae; genus unknown;species 558 <0.05  
Enterobacteriaceae; genus unknown; species 449 <0.05  
Bifidobacterium genus <0.05  
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Table 3. Changes in bacterial taxa during and after intervention in the prebiotic group
1 Non-parametric repeated measures Friedman test. 




Parabacteroides distasonis <0.01  
Clostridiaceae; genus unknown; species 319 <0.02  
Ruminococcaceae ;genus unknown; species 118 <0.02  
Lachnospiraceae; genus unknown; species 40 <0.02  
Oscillospira; species 52 <0.02  
Oscillospira; species 409 <0.03  
Lachnospiraceae ;genus unknown; species 783 <0.03  
Barnesiellaceae; genus unknown; species 542 <0.05  
Christensenellaceae ;genus unknown; species 497 <0.05  
Ruminococcus; species 584 <0.05  
Bilophila wadsworthia <0.05  




Lachnospiraceae; genus unknown; species 19 <0.01  
Bacteroides; species 119 <0.02  
Clostridiales; genus unknown; species 171 <0.02  
Peptococcaceae; genus unknown; species 373 <0.03  
Veillonellaceae; genus unknown; species 284 <0.03  
Lachnospiraceae; genus unknown; species 206 <0.03  
Bacteroides; species 124 <0.05  
Clostridiales; genus unknown; species 410 <0.05  
Ruminococcaceae; genus unknown; species 130 <0.05  
Ruminococcaceae; genus unknown; species 592 <0.05  
Alphaproteobacteria; genus unknown; species 223 <0.05  
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Number of daytime anal gas evacuations during the last 2 days of each evaluation phase: pre-treatment 
(Pre: days 3-4, white), treatment (Tx: days 31-32, black) and post-treatment (Post: days 48-49, grey) (LFD 
n=21; prebiotic group n=19).  
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Effect of challenge diet on symptoms measured by daily questionnaires pre-treatment (days 5-7, white) and 
in the treatment phase (days 33-35, black) (LFD n=21; prebiotic group n=19). Data are average over each 
3-day periods. In each group the change during treatment from pre-treatment phase is shown.  
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Symptoms in response to probe meal in the pre-treatment (day 5, white) and in the treatment phase (day 
33, black) (LFD n=21; prebiotic group n=19).  
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Effect of treatment on relative abundance in Bifidobacterium and Bilophila wadsworthia. Figure shows 
changes during treatment (from pre-treatment phase) and after treatment (from treatment phase). Overall 
differences were tested by non-parametric Kruskal-Wallis analysis of variance on ranks, and the Mann-
Whitney test was used for post-hoc comparisons (LFD n=21; prebiotic group n=19). Data are median and 
interquartile range.  
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Supplemental material: microbiota analysis 
Genomic DNA extraction. A frozen aliquot (250 mg) of each sample was 
suspended in 250 µL of guanidine thiocyanate, 0.1 M Tris (pH 7.5), 40 µL of 
10% N-lauroyl sarcosine and 500 µL of 5% N-lauroyl sarcosine. DNA was 
extracted by mechanical disruption of microbial cells with beads, and the 
recovery of nucleic acids from the clear lysates was achieved by alcohol 
precipitation, as previously described 1. An equivalent of 1 mg of each sample 
was used for DNA quantification using a NanoDrop ND-1000 
spectrophotometer (Nucliber, Madrid, Spain).  
High-throughput DNA sequencing. To profile the microbiome 
composition, the hyper-variable region (V4) of the bacterial and archaeal 16S 
rRNA gene was amplified by PCR. On the basis of our analysis performed using 
PrimerProspector software 2, the V4 primer pairs used in this study were 
expected to amplify almost 100% of the bacterial and archaeal domains. The 5’ 
ends of the forward (V4F_515_19: 5’- GTGCCAGCAMGCCGCGGTAA -3’) and 
reverse (V4R_806_20: 5’- GGACTACCAGGGTATCTAAT -3’) primers targeting 
the 16S gene were tagged with specific sequences as follows: 5’-
{AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGT} 
{GTGCCAGCMGCCGCGGTAA}-3’ and 5’-
{CAAGCAGAAGACGGCATACGAGAT} {Golay barcode} {AGTCAGTCAGCC} 
{GGACTACHVGGGTWTCTAAT}-3’. Multiplex identifiers, known as Golay 
codes, had 12 bases and were specified downstream of the reverse primer 
sequence (V4R_806_20) 3. Standard PCR (0.75 units of Taq polymerase 
(Roche, Barcelona, Spain) and 20 pmol/µL forward and reverse primers) was 
run in a Mastercycler gradient (Eppendorf, Madrid, Spain) at 94°C for 3 min, 
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followed by 35 cycles at 94°C for 45 sec, 56°C for 60 sec, 72°C for 90 sec, and 
a final cycle of 72°C for 10 min. Amplicons were purified using a QIAquick PCR 
Purification Kit (Qiagen, Barcelona, Spain), quantified using a NanoDrop ND-
1000 spectrophotometer (Nucliber, Madrid, Spain), and then pooled in equal 
concentrations. Pooled amplicons (2 nM) were then subjected to sequencing 
using Illumina MiSeq technology in the technical support unit of the 
Autonomous University of Barcelona (UAB, Spain) following standard Illumina 
platform protocols. 
Sequence analysis. Sequences obtained from the 60 faecal samples 
after the sequencing step were analysed with QIIME (Quantitative Insights into 
Microbial Ecology) 
1.9.1 4 using an in-house script that performs upstream and downstream 
analyses. Low-quality raw sequences with a Phred score of less than 20 were 
removed from the analysis. Each read was assigned back to its corresponding 
sample during a demultiplexing step, and the barcodes were removed from the 
sequences. After filtering, we obtained a total of 2,460,589 high-quality 
sequences. The USEARCH (ultra-fast sequence analysis) 5 tool was used to 
cluster similar sequences into operational taxonomic units (OTUs) or taxa 
based on a 97% similarity level, and the UCHIME (ultra-fast chimeric search) 
algorithm was used to remove chimeric sequences. From each of the OTUs, 
one representative sequence was selected and then aligned using PyNAST 
(Python Nearest Alignment Space Termination tool) against a Greengenes 
template alignment from the most recent version of the database (gg_13_8). 
Then, a taxonomical assignment step was performed using the basic local 
alignment search tool (BLAST) to map each representative sequence against a 
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combined database encompassing the Greengenes and PATRIC 
(Pathosystems Resource Integration Center) databases. A phylogenetic tree 
was constructed using the FastTree programme and an OTU table. To avoid 
false positive OTUs, we eliminated those that did not represent at least 0.2% of 
the sequences in at least two samples. The final OTU table was rarefied at 
15396 sequence reads per sample. Rarefaction is used to overcome cases in 
which read counts were not similar between samples. 
Quantification of Bifidobacterium. To quantify Bifidobacterium spp., the 
extracted genomic DNA was used to amplify the 16S rRNA gene by quantitative 
real-time PCR (qPCR) using the following specific primers: Bifgenus_F (5’-TGG 
CTC AGG ATG AAC GCT G-3’), Bifgenus_R (5’-TGA TAG GAC GCG ACC 
CCA T-3’) and the TaqMan MGB probe (FAMTM dye-labelled; 5’-CAT CCG GCA 
TTA CCA-3’). To calibrate the qPCR reactions, we used calculated amounts of 
extracted DNA from three isolated Bifidobacterium species (B. breve, B. longum 
and B. infantis). Serial dilutions of the pooled DNA were amplified (copy number 
ranging from 25 to 2.5x106) to extrapolate the bifidobacterial number in each 
sample. The qPCR was performed with the 7500 Fast Real-Time PCR system 
(Applied Biosystems, Barcelona, Spain) using optical-grade 96-well plates. The 
PCR reaction was performed in a total volume of 25 µL using the TaqMan 
Universal PCR Master Mix (Applied Biosystems), containing 300 nM of each 
primer and 100 nM of the MGB probe. The reaction conditions for the 
amplification of DNA were 50ºC for 2 min, 95ºC for 10 min, 40 cycles of 95ºC for 
15 sec and 60ºC for 1 min. All reactions were performed in triplicate, and the 
mean values were calculated. The data were analysed using Sequence 
Detection Software version 1.4, supplied by Applied Biosystems. 
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